{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:35:58Z","timestamp":1790094958024,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2025ZNSFSC0239"],"award-info":[{"award-number":["2025ZNSFSC0239"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032579","name":"Beijing Medical Award Foundation","doi-asserted-by":"publisher","award":["YXJL-2024\\u20130350-0177"],"award-info":[{"award-number":["YXJL-2024\\u20130350-0177"]}],"id":[{"id":"10.13039\/100032579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2020\\u201310-122"],"award-info":[{"award-number":["320.6750.2020\\u201310-122"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HR2020MS-0484"],"award-info":[{"award-number":["Y-HR2020MS-0484"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejrad.2025.112401","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:08:20Z","timestamp":1756768100000},"page":"112401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study"],"prefix":"10.1016","volume":"192","author":[{"given":"Li-Wei","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Feng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Li","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2025.112401_b0005","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-263. https:\/\/doi: 10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"10.1016\/j.ejrad.2025.112401_b0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2036.2012.05174.x","article-title":"Potentially curative treatment in patients with hepatocellular cancer\u2013results from the liver cancer research network","volume":"36","author":"Kanwal","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejrad.2025.112401_b0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.21037\/hbsn.2018.02.07","article-title":"Laparoscopic liver resection: the current status and the future","volume":"7","author":"Cai","year":"2018","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"2022","key":"10.1016\/j.ejrad.2025.112401_b0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejrad.2025.112401_b0025","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.ejrad.2025.112401_b0030","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2025.112401_b0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13046-021-01968-w","article-title":"Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets","volume":"40","author":"Luo","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejrad.2025.112401_b0040","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2025.112401_b0045","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2025.112401_b0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2025.112401_b0055","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12072-021-10184-9","article-title":"Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study","volume":"15","author":"Fu","year":"2021","journal-title":"Hep. Intl."},{"key":"10.1016\/j.ejrad.2025.112401_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000531377","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ejrad.2025.112401_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108634","article-title":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"257","author":"Wang","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejrad.2025.112401_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejrad.2025.112401_b0075","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejrad.2025.112401_b0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2025.112401_b0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejrad.2025.112401_b0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ejrad.2025.112401_b0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2025.112401_b0100","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejrad.2025.112401_b0105","article-title":"Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: an international observational study","volume":"7","author":"Xia","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ejrad.2025.112401_b0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.31022","article-title":"Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach","volume":"72","author":"Han","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejrad.2025.112401_b0115","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","article-title":"A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer","volume":"24","author":"Kadalayil","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejrad.2025.112401_b0120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/liv.12878","article-title":"Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score","volume":"36","author":"Park","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.ejrad.2025.112401_b0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/liv.13029","article-title":"Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma","volume":"36","author":"Cappelli","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.ejrad.2025.112401_b0130","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas Research N. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017;169:1327-1341 e1323. doi: 10.1016\/j.cell.2017.05.046.","DOI":"10.1016\/j.cell.2017.05.046"},{"key":"10.1016\/j.ejrad.2025.112401_b0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejrad.2025.112401_b0140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","article-title":"Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial","volume":"174","author":"Lai","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejrad.2025.112401_b0145","article-title":"Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejrad.2025.112401_b0150","doi-asserted-by":"crossref","first-page":"11315","DOI":"10.1002\/cam4.5841","article-title":"Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features","volume":"12","author":"Zou","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejrad.2025.112401_b0155","article-title":"Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: multicenter retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejrad.2025.112401_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008953","article-title":"Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy","volume":"12","author":"Hua","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejrad.2025.112401_b0165","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00330-020-07078-z","article-title":"The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization","volume":"31","author":"Zhang","year":"2021","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112401_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111510","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma","volume":"130","author":"Liu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejrad.2025.112401_b0175","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12072-023-10613-x","article-title":"The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors","volume":"18","author":"Zeng","year":"2024","journal-title":"Hep. Intl."},{"key":"10.1016\/j.ejrad.2025.112401_b0180","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s12072-020-10032-2","article-title":"Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study","volume":"14","author":"Chen","year":"2020","journal-title":"Hep. Intl."},{"key":"10.1016\/j.ejrad.2025.112401_b0185","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2025.112401_b0190","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1007\/s00330-020-06931-5","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE","volume":"30","author":"Schobert","year":"2020","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2025.112401_b0195","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1089\/10799900260286623","article-title":"Role of blood platelets in infection and inflammation","volume":"22","author":"Klinger","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejrad.2025.112401_b0200","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00464-018-6426-3","article-title":"Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry","volume":"33","author":"Levi Sandri","year":"2019","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.ejrad.2025.112401_b0205","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1148\/radiol.2423060220","article-title":"Internal mammary arteries supplying hepatocellular carcinoma: vascular anatomy at digital subtraction angiography in 97 patients","volume":"242","author":"Kim","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112401_b0210","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1148\/rg.2017160122","article-title":"Chemoembolization of hepatocellular carcinoma with extrahepatic collateral blood supply: anatomic and technical considerations","volume":"37","author":"Moustafa","year":"2017","journal-title":"Radiographics"},{"key":"10.1016\/j.ejrad.2025.112401_b0215","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25004875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25004875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:42:05Z","timestamp":1771256525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X25004875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"alternative-id":["S0720048X25004875"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112401","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112401"}}